Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : IDPH--Positive preliminary results for pivotal trial of ID -- Ignore unavailable to you. Want to Upgrade?

To: Maurice Winn who wrote (1521)	4/1/1998 11:10:00 PM
From: DMB	1 Recommendation Read Replies (1) \| Respond to of 1762

The large majority of patients with low grade lymphoma at any one time are doing just fine without any treatment. At some point they all can be expected to progress and need treatment of one sort or another. However, in my own practice (which must include dozens of patients with this diagnosis) I have only one in the last 3 months that has take a turn for the worse and for whom I have begun Rituxan (he had had a course of chemotherapy several years ago and was very eager to try something different).